Disrupt PAD III

Shockwave IVL maintains superiority to angioplasty in calcified peripheral disease at two years

Shockwave Medical announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with intravascular lithotripsy (IVL) led to...

RANZCR releases statement on iodinated contrast media shortage

The Royal Australian and New Zealand College of Radiologists (RANZCR) has issued a statement addressing the Australian and global shortage of iodinated contrast media. The...

EuroPCR 2022: Studies underscore potential of renal denervation as an adjunctive therapy for hypertension

Late-breaking trial data presented at EuroPCR 2022 (17–20 May, Paris, France) underscore the potential of renal denervation as an adjunctive therapy to treat hypertension,...

Vivasure Medical announces Series D financing to advance portfolio of PerQseal vessel closure devices

Vivasure Medical has announced the closing of the first tranche of €22 million (US$23 million) as part of its Series D financing round that...

Karim Valji


Laura Crocetti

Maureen Kohi